AI-Powered Precision Medicine: MarkerX Leading the Way in Early Cancer Detection

We are thrilled to announce that MarkerX has been selected for inclusion in “Taiwan’s AI Startup Map 2024” jointly published by the Artificial Intelligence Foundation (AIF) and Taiwan AI Cloud on November 25th. This map primarily features startups established within the past eight years and classifies them based on the infrastructure and vertical industry applications required for AI implementation.

This recognition underscores our continuous innovation and efforts in the AI-driven healthcare sector and serves as a testament to the professional acknowledgment of MarkerX’s AI multi-indicator algorithm in the AI startup landscape.

AI and Healthcare: A New Era of Collaboration

Observing the companies listed on the map, we see a burgeoning trend of AI applications in the healthcare industry, particularly in early disease prevention. For instance, MarkerX employs AI-driven mass spectrometry analysis combined with proteomics knowledge to develop AI-based multi-cancer early detection, enabling precise analysis of biomarkers in blood and achieving early screening for multiple cancer types. This not only enhances the accuracy of cancer diagnosis but also provides patients with better treatment timing.

Why has Taiwan’s AI startup scene started to shine in the healthcare sector?

• Data-Driven Innovation: Investments in data infrastructure over the past decade have laid a solid foundation for the development of AI in healthcare.
• Industry Applications: AI is no longer a distant concept but has effectively addressed pain points in the healthcare industry, creating commercial value.
• Emergence of Startups: The flourishing of AI startups in Taiwan has injected new vitality and innovative thinking into the healthcare industry.

In addition to MarkerX, other featured medical AI startups have their own unique characteristics:

• v5med:
  Established in 2014, v5med develops AI-based optical inspection and measurement products to meet market demands for automated optical inspection and measurement.
• Preteeth (now Dentscape):
  Applies artificial intelligence to dental simulation technology, automatically designing dental prostheses such as crowns, bridges, and occlusal splints.
• AHEAD Medicine:
  Founded in 2017, AHEAD launched the Cyto-copilot platform, revolutionizing the data analysis workflow of flow cytometry. It has established a partnership with BD Biosciences, the world’s largest flow cytometer manufacturer.

The success of these startups attests to the immense potential of AI in the healthcare industry, especially in precision medicine.

MarkerX’s Future Outlook

MarkerX will continue to delve deep into the field of AI-based early disease prevention, providing more comprehensive health management solutions for global patients through innovative technologies such as AI-based multi-cancer early detection. In the future, we will continue to strive in the following areas:

• Expanding the Biomarker Database: Covering more cancer types to enhance the breadth of screening.
• Deepening Clinical Collaboration: Collaborating with more medical centers to accelerate clinical validation.
• Building an Open Ecosystem: Working with global partners to promote the development of AI in healthcare.

MarkerX believes that through continuous innovation and collaboration, we will bring more possibilities to Taiwan’s healthcare industry and reach out to the world, bringing hope to more cancer patients and countless families.

About MarkerX

MarkerX is a biotech startup focused on precision medicine. Our vision is to achieve early cancer prevention through AI-driven blood screening. Our core product, AI Proteomics Early Cancer Screening, combines the high precision of mass spectrometry with the powerful analytical capabilities of AI multi-indicator algorithms, bringing more possibilities to cancer patients and their families worldwide. Our core value is to provide the best screening technology for cancer prevention, accompany medical teams in continuous advancement, and empower more lives to create infinite value.